Stage III Non-small Cell Lung Cancer Clinical Trial
Official title:
Construction of CT Radiomics Model to Assess PD-L1 Status and Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves both progression-free survival and overall survival. However, a substantial proportion of patients still experience disease recurrence despite consolidation ICI. It is important for personalized treatment to predict the efficacy of consolidation ICI. PD-L1 expression is used as a predictive biomarker for ICI response and efficacy in advanced NSCLC, but its role in patients with stage III disease is unclear. One important reason is PD-L1 testing performed on pre-CRT tissue may not reflect changes in PD-L1 expression after CRT. CT-based radiomics approaches have been successfully applied to generate imaging biomarkers as decision support tools for clinical practice. The hypothesis of this study is that CT radiomics model can assess PD-L1 status after CRT and predict the efficacy of CRT combined with ICI in unresectable locally advanced NSCLC.
This is an observational longitudinal prospective study. CT scan is performed before radiotherapy, during radiotherapy and at the end of radiotherapy in patients with unresectable locally advanced NSCLC who undergo CRT. Radiomic features were extracted from CT images and baseline PD-L1 expression is assessed. CT-based radiomics models is developed to assess PD-L1 expression and predict the efficacy of ICI. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05488626 -
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
|
N/A | |
Recruiting |
NCT02076282 -
MRI Optimization Study in Stage III NSCLC
|
N/A | |
Terminated |
NCT01577212 -
Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy
|
Phase 2 | |
Withdrawn |
NCT01336543 -
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01102231 -
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06082492 -
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03049618 -
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
|
Phase 2 | |
Recruiting |
NCT03077854 -
Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
|
N/A | |
Recruiting |
NCT05157542 -
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
|
Phase 1 | |
Recruiting |
NCT00938418 -
Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05361174 -
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03048500 -
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Not yet recruiting |
NCT05891080 -
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
|
Phase 2 | |
Active, not recruiting |
NCT01948141 -
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
|
Phase 2 | |
Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
Recruiting |
NCT05157503 -
Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
|
||
Recruiting |
NCT05468242 -
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
|
Phase 2 | |
Active, not recruiting |
NCT06102057 -
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
|
Phase 2 |